Variability in blood-based amyloid-β assays: The need for consensus on pre-analytical processing

Journal of Alzheimer's Disease

Volumn 30, Issue 2, 2012, Pages 323-336

  Watt, Andrew D ^a,b   Perez, Keyla A ^a,b   Rembach, Alan R ^a   Masters, Colin L ^a   Villemagne, Victor L ^a,c   Barnham, Kevin J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

Alzheimer's disease; amyloid ; biomarkers; blood; plasma; protocol; standardized

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; EDETIC ACID; POLYPROPYLENE; PROSTAGLANDIN E1; TAU PROTEIN;

ALZHEIMER DISEASE; ANALYTIC METHOD; BLOOD SAMPLING; BODY FLUID; CENTRIFUGATION; CEREBROSPINAL FLUID ANALYSIS; CONSENSUS; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZE THAWING; HUMAN; MASS SCREENING; NEUROIMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING; REVIEW;

EID: 84861487349     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120058     Document Type: Review

References (124)

1. Selkoe DJ (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17, 1060-1065.
2. Sperling RA, Jack CR, Aisen PS (2011) Testing the right target and right drug at the right stage. Sci Transl Med 3, 111cm133.
3. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
4. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, Faux NG, Masters CL, Barnham KJ (2010) Blood borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 30, 6315-6322.
5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
6. Alzheimer's Disease International (2009), World Alzheimer Report. Prince M, Jackson J, eds. ADI, London, 25-45.
7. Humpel C (2011) Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 29, 26-32.
8. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
9. Marksteiner J, Hinterhuber H, Humpel C (2007) Cere-brospinal fluid biomarkers for diagnosis of Alzheimer's disease: Beta-amyloid (1-42), tau, phospho-tau-181 and total protein. Drugs Today 43, 423-431. (Pubitemid 47234772)
10. Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D (2005) Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 19, 220-225. (Pubitemid 44366623)
11. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050. (Pubitemid 44684524)
12. Tammen H, Schulte I, Hess R, Menzel C, Kellmann M, Mohring T, Schulz-Knappe P (2005) Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display. Proteomics 5, 3414-3422. (Pubitemid 41192047)
13. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 120, 545-555. (Pubitemid 40269768)
14. Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics. J Neurochem 97, 1700-1725. (Pubitemid 43873662)
15. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma Afj40 and Afj42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology 61, 1185-1190. (Pubitemid 37377535)
16. Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. Neuro Rx 1, 226-234. (Pubitemid 46591884)
17. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid b-protein levels. Arch Neurol 60, 958-964. (Pubitemid 36858355)
18. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid ((1-42)) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
19. Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sab-bagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5, 18-29.
20. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wis-niewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105 (Pubitemid 30027637)
21. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S (2009) No correlation between time-linked plasma and CSF A beta levels. Neurochem Int 55, 820-825.
22. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN, Grp AR (2010) Plasma amyloid-beta as a biomarker in Alzheimer's disease: The AIBL Study of Aging. J Alzheimers Dis 20, 1233-1242.
23. Alzheimer's Disease Neuroimaging Network, Alzheimer's Disease Neuroimaging Protocol, http://www.adni-info.org/Scientists/Pdfs/adni-protocol-9- 19-08.pdf, Accessed 22 September 2011.
24. Alzheimer's Disease Neuroimaging Network, ADNI Procedures Manual, http://www.adni-info.org/Scientists/Pdfs/adniproceduresmanual12.pdf, Accessed 22 September 2011.
25. Dominantly Inherited Alzheimer Network, Accessing biological fluids from the DIAN Biomarker Core, http://www.dian-info.org/resourcedb/PDFs/Biomarker.pdf, Accessed 22 September 2011.
26. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rüther E, Kornhuber J, Wiltfang J (2004) Cerebrospinal fluid amyloid b peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid b peptides. Electrophoresis 25, 2912-2918. (Pubitemid 39294839)
27. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: Implications for use in clinical practice. Clin Chem 51, 189-195. (Pubitemid 40024030)
28. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hem-merMd B, Tumani H, Deisenhammer F (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914-1922.
29. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, pii: 986310.
30. Lachno D, Vanderstichele H, De Groote G, Kostanjevecki V, De Meyer G, Siemers E, Willey M, Bourdage J, Konrad R, Dean R (2009) The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma fj-amyloid isoforms using the INNO-BIA plasma Afj forms multiplex assay. J Nutr Health Aging 13, 220-225.
31. Plebani M (2006) Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med 44, 750-759. (Pubitemid 43832871)
32. Zetterberg H (2008) Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease? Recent Pat CNS Drug Discov 3, 109-111.
33. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of b-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
34. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zim-mermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid {beta} peptides. Clin Chem 52, 332-334. (Pubitemid 43185505)
35. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid fj-amyloid (1-42) in Alzheimer disease-differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680.
36. Carrette O, Burkhard PR, Hughes S, Hochstrasser DF, Sanchez J-C (2005) Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process? Proteomics 5, 3060-3065. (Pubitemid 41176472)
37. You J-S, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE (2005) The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 5, 290-296. (Pubitemid 40189659)
38. Maruyama M, Higuchi M, Takaki Y, Matsuba Y, Tanji H, Nemoto M, Tomita N, Matsui T, Iwata N, Mizukami H, Muramatsu S, Ozawa K, Saido TC, Arai H, Sasaki H (2005) Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol 57, 832-842. (Pubitemid 40798621)
39. Murphy M, LeVine H (2010) Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 19, 311-323.
40. Shii K, Yokono K, Baba S, Roth RA (1986) Purification and characterization of insulin-degrading enzyme from human erythrocytes. Diabetes 35, 675-683. (Pubitemid 16088345)
41. Berven FS, Kroksveen AC, Berle M, Rajalahti T, Flikka K, Arneberg R, Myhr K-M, Vedeler C, Kvalheim OM, Ulvik RJ (2007) Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. PROTEOMICS Clin Appl 1, 699-711.
42. West-Nielsen M, Høgdall EV, Marchiori E, Høgdall CK, Schou C, Heegaard NHH (2005) Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem 77, 5114-5123. (Pubitemid 41140826)
43. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE (2008) Standard operating procedures for serum and plasma collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. J Proteome Res 8, 113-117.
44. Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL, Villemagne VL, Barnham KJ (2010) Increasing the predictive accuracy of amyloid-beta blood-borne biomarkers in Alzheimer's disease. J Alzheimers Dis 24, 47-59.
45. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R for the Texas Alzheimer's Research Consortium (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077-1081.
46. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5, 55-59.
47. Cavani S, Tamaoka A, Moretti A, Marinelli L, Angelini G, Di Stefano S, Piombo G, Cazzulo V, Matsuno S, Shoji S, Furiya Y, Zaccheo D, Dagna-Bricarelli F, Tabaton M, Mori H (2000) Plasma levels of amyloid fj 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet 95, 224-228.
48. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem Biophys Res Commun 268, 750-756. (Pubitemid 30150863)
49. Tokuda T, Tamaoka A, Matsuno S, Sakurai S, Shimada H, Morita H, Ikeda S (2001) Plasma levels of amyloid fj proteins did not differ between subjects taking statins and those not taking statins. Ann Neurol 49, 546-547. (Pubitemid 32281346)
50. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR (2002) Serum creatinine levels correlate with plasma amyloid fj protein. Alzheimer Dis Assoc Disord 16, 187-190. (Pubitemid 35001095)
51. Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S (2002) Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord 14, 156-160.
52. Noonan CW, Reif JS, Burch JB, Ichinose TY, Yost MG, Magnusson K (2002) Relationship between amyloid fj protein and melatonin metabolite in a study of electric utility workers. J Occup Environ Med 44, 769-775.
53. Bornebroek M, De Jonghe C, Haan J, Kumar-Singh S, Younkin S, Roos R, Van Broeckhoven C (2003) Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbPP 693): Decreased plasma amyloid-fj 42 concentration. Neu-robiolDis 14, 619-623. (Pubitemid 37543538)
54. Fujiwara Y, Takahashi M, Tanaka M, Hoshi T, Someya T, Shinkai S (2003) Relationships between plasma beta-amyloid peptide 1-42 and atherosclerotic risk factors in community-based older populations. Gerontology 49, 374-379. (Pubitemid 37465117)
55. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-proteinlevels. Arch Neurol 60, 958-964. (Pubitemid 36858355)
56. Ishii K, Tokuda T, Matsushima T, Miya F, Shoji S, Ikeda S, Tamaoka A (2003) Pravastatin at 10mg/day does not decrease plasma levels of either amyloid-fj (Afj) 40 or Afj 42 in humans. Neurosci Lett 350, 161-164. (Pubitemid 37205190)
57. Olsson A, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K (2003) Unaltered plasma levels of beta-amyloid (1-40) and beta-amyloid (1-42) upon stimulation of human platelets. Dement Geriatr Cogn Disord 16, 93-97. (Pubitemid 36677102)
58. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clio-quinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691. (Pubitemid 37521621)
59. Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M (2004) Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63, 828-831. (Pubitemid 39297642)
60. Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K (2004) Plasma levels of beta-amyloid (1-40), beta-amyloid (1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61, 333-337. (Pubitemid 38327348)
61. Smith CCT, Betteridge DJ (2004) Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans. Neurosci Lett 367, 48-50. (Pubitemid 39078782)
62. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MM (2004) Plasma amyloid fj, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55, 570-575. (Pubitemid 38391975)
63. Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA, Newton R, Gandy SE, Martins RN (2005) Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis 8, 269-282.
64. Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, Hyman BT, Growdon JH, Greenberg SM, Bot-tiglieri T (2005) Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 65, 1402-1408. (Pubitemid 41552769)
65. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM (2006) Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66, 23-29. (Pubitemid 43739586)
66. Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, Plymate SR, Asthana S, Rhoads K, Mehta PD, Craft S (2006) Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 66, 1506-1510. (Pubitemid 43958544)
67. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C (2006) Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27, 904-905. (Pubitemid 44287903)
68. Pomara N, Doraiswamy PM, Willoughby LM, Roth AE, Mulsant BH, Sidtis JJ, Mehta PD, Reynolds CF 3rd, Pollock BG (2006) Elevation in plasma Abeta42 in geriatric depression: A pilot study. Neurochem Res 31, 341-349. (Pubitemid 43829323)
69. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MMB (2006) Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol 5, 655-660. (Pubitemid 44062411)
70. Abdullah L, Paris D, Luis C, Quadros A, Parrish J, Valdes L, Keegan AP, Mathura V, Crawford F, Mullan M (2007) The influence of diagnosis, intra-and inter-person variability on serum and plasma A beta levels. Neurosci Lett 428, 53-58. (Pubitemid 350051180)
71. Bibl M, Esselmann H, Mollenhauer B, Weniger G, Welge V, Liess M, Lewczuk P, Otto M, Schulz JB, Trenkwalder C, Kornhuber J, Wiltfang J (2007) Blood-based neurochemical diagnosis of vascular dementia: A pilot study. J Neurochem 103, 467-474. (Pubitemid 47498016)
72. Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund L-O, Ingelsson M, Lannfelt L (2007) The normal equilibrium between CSF and plasma amyloid beta levelsisdisruptedinAlzheimer's disease. Neurosci Lett427, 127-131. (Pubitemid 47633799)
73. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362. (Pubitemid 46425689)
74. Luchsinger JA, Tang M-X, Miller J, Green R, Mehta PD, Mayeux R (2007) Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res 32, 775-781. (Pubitemid 46481307)
75. Maler JM, Klafki H-W, Paul S, Spitzer P, Groemer TW, Henkel AW, Esselmann H, Lewczuk P, Kornhuber J, Wilt-fang J (2007) Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: Evidence for novel Abeta species. Proteomics 7, 3815-3820. (Pubitemid 350022287)
76. Qiu WQ, Sun X, Selkoe DJ, Mwamburi DM, Huang T, Bhadela R, Bergethon P, Scott TM, Summergrad P, Wang L, Rosenberg I, Folstein M (2007) Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 22, 536-542. (Pubitemid 46951751)
77. Slemmon JR, Painter CL, Nadanaciva S, Catana F, Cook A, Motter R, Seubert P (2007) Distribution of Abeta peptide in whole blood. J Chromatogr B Analyt Technol Biomed Life Sci 846, 24-31. (Pubitemid 46149484)
78. Sobow T, Flirski M, Liberski PP, Kloszewska I (2007) Plasma A beta levels as predictors of response to rivastig-mine treatment in Alzheimer's disease. Acta Neurobiol Exp 67, 131-139. (Pubitemid 47066465)
79. Ait-ghezala G, Abdullah L, Volmar CH, Paris D, Luis CA, Quadros A, Mouzon B, Mullan MA, Keegan AP, Parrish J, Crawford FC, Mathura VS, Mullan MJ (2008) Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. Cytokine 44, 283-287.
80. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P (2008) Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 29, 1-11. (Pubitemid 350102708)
81. Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, Hutton ML, Younkin SG, Graff-Radford NR (2008) Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70, 596-606. (Pubitemid 351294637)
82. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid beta production withagamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65, 1031-1038.
83. Flicker L, Martins RN, Thomas J, Acres J, Taddei K, Vasikaran SD, Norman P, Jamrozik K, Almeida OP (2008) B-vitamins reduce plasma levels of beta amyloid. Neurobiol Aging 29, 303-305.
84. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
85. Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, Irizarry MC (2008) Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65, 776-785. (Pubitemid 351831455)
86. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70, 1664-1671. (Pubitemid 351644132)
87. Mamo JCL, Jian L, James AP, Flicker L, Esselmann H, Wiltfang J (2008) Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease ormild cognitive impairment. Ann Clin Biochem 45, 395-403. (Pubitemid 352031547)
88. Modrego PJ, Monleon I, Sarasa M (2008) The clinical significance of plasmatic amyloid A beta-40 peptide levels in Alzheimer's disease patients treated with galantamine. Am J Alzheimers Dis Other Dement 23, 286-290. (Pubitemid 351852607)
89. Santos AN, Simm A, Holthoff V, Boehm G (2008) Amethod for the detection of amyloid-beta {1-40}, amyloid-beta {1-42} and amyloid-beta oligomers in blood using magnetic beadsincombination withflow cytometry anditsapplication in the diagnostics of alzheimer's disease. J Alzheimers Dis 14, 127-131. (Pubitemid 352040031)
90. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R (2008) Peripheral A {beta} subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 105, 14052-14057.
91. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingels-son E, Ronnemaa E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: A prospective, population-based cohort study. Arch Neurol 65, 256-263. (Pubitemid 351240790)
92. Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M (2008) Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 1219, 169-179.
93. Abdo WF, van Mierlo T, Hengstman GJ, Schelhaas HJ, van Engelen BG, Verbeek MM (2009) Increased plasma amyloid-beta (42) protein in sporadic inclusion body myosi-tis. Acta Neuropathol 118, 429-431.
94. Cammarata S, Borghi R, Giliberto L, Pardini M, Pollero V, Novello C, Fornaro M, Vitali A, Bracco L, Caltagirone C, Bossu P, Odetti P, Tabaton M (2009) Amyloid-beta42 plasma levels are elevatedinamnestic mild cognitive impairment. J Alzheimers Dis 18, 267-271.
95. Ditto NT, Kline TR, Alfinito PD, Slemmon JR (2009) Enrichment and analysis of Alzheimer's A beta 1-42 peptide in human plasma and whole blood. J Neurosci Meth 182, 260-265.
96. Evered LA, Silbert BS, Scott DA, Maruff P, Laughton KM, Volitakis I, Cowie T, Cherny RA, Masters CL, Li Q-X (2009) Plasma amyloid beta42 and amyloid beta40 levels are associated with early cognitive dysfunction after cardiac surgery. Ann Thorac Surg 88, 1426-1432.
97. Gomis M, Sobrino T, Ois A, Millan M, Rodŕiguez-Campello A, de la Ossa NP, Rodŕiguez-Gonzalez R, Jimenez-Conde J, Cuadrado-Godia E, Roquer J, Davalos A (2009) Plasma fj-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke 40, 3197-3201.
98. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bog-stedt A, Frolich L, Schroder J, Schonknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Moller HJ, Kurz A, Basun H (2009) Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70, 922-931.
99. Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P (2009) Association of plasma amyloid beta with risk of dementia: The prospective Three-City Study. Neurology 73, 847-853.
100. Lee Y-H, Martin JM, Maple RL, Tharp WG, Pratley RE (2009) Plasma amyloid-beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals. Neuroendocrinology 90, 383-390.
101. Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS (2009) The relationship of plasma Abeta levels to dementia in aging individuals with down syndrome. Alzheimer Dis Assoc Disord 23, 315-318.
102. Okereke OI, Xia W, Selkoe DJ, Grodstein F (2009) Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 66, 1247-1253.
103. Sedaghat F, Dedousi E, Costa V, Dimitriadis AS, Baloy-annis SJ (2009) Plasma levels of amyloid beta1-42 are independent of neuronal function in Alzheimer's disease. J Alzheimers Dis 17, 343-348.
104. Sun X, Chiu CC, Liebson E, Crivello NA, Wang L, Claunch J, Folstein M, Rosenberg I, Mwamburi DM, Peter I, Qiu WQ (2009) Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Dis Assoc Disord 23, 238-244.
105. Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC (2009) Plasma A beta, homocysteine, and cognition The Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 72, 268-272.
106. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66, 190-199.
107. Conti E, Galimberti G, Piazza F, Raggi ME, Ferrarese C (2010) Increased soluble APP alpha, Abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from Down syndrome patients. Alzheimer Dis Assoc Dis 24, 96-100.
108. Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX, Schupf N, Mayeux RP (2010) Plasma beta-Amyloid and Cognitive Decline. Arch Neurol 67, 1485-1490.
109. Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H, Kilander L (2010) Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord 29, 204-212.
110. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta (40) and Abeta (42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367.
111. Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blanken-stein MA (2010) Evaluation of plasma A beta 40 and A beta 42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 539-540.
112. Laske C, Sopovab K, Gkotsisb C, Eschweilera GW, Stratena G, Gawazb M, Leyhea T, Stellosb K (2010) Amyloid-beta peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. J Alzheimers Dis 21, 1263-1269.
113. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Burger K, Hampel H, Frolich L, Henn F, Falkai P, Ruther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schroder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J (2010) Amyloid fj peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 223, 366-370.
114. Oh ES, Mielke MM, Rosenberg PB, Jain A, Fedarko NS, Lyketsos CG, Mehta PD (2010) Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-beta in plasma. J Alzheimers Dis 21, 769-773.
115. Prasher VP, Sajith SG, Mehta P, Zigman WB, Schupf N (2010) Plasma fj-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry 25, 202-207.
116. Reitz C, van Rooij FJA, Soares HD, de Maat MPM, Hofman A, Witteman JCM, Breteler MMB (2010) Matrix metallo-proteinase 3 haplotypes and plasma amyloid beta levels: The Rotterdam Study. Neurobiol Aging 31, 715-718.
117. Seppala TT, Herukka S-K, Hanninen T, Tervo S, Hallikainen M, Soininen H, Pirttila T (2010) Plasma Afj42 and Afj40 as markers of cognitive change in follow-up: A prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81, 1123-1127.
118. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33, 67-73.
119. Devanand DP, Schupf N, Stern Y, Parsey R, Pelton GH, Mehta P, Mayeux R (2011) Plasma A beta and PET PiB binding are inversely related in mild cognitive impairment. Neurology 77, 125-131.
120. Fei M, Jianghua W, Rujuan M, Wei Z, Qian W (2011) The relationship of plasma Abeta levels to dementia in aging individuals with mild cognitive impairment. J Neurol Sci 305, 92-96.
121. Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT (2011) Plasma amyloid-fj as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis 23, 399-409.
122. Kitaguchi N, Kawaguchi K, Nakai S, Murakami K, Ito S, Hoshino H, Hori H, Ohashi A, Shimano Y, Suzuki N, Yuzawa Y, Mutoh T, Sugiyama S (2011) Reduction of Alzheimer's disease amyloid-beta in plasma by hemodialysis and its relation to cognitive functions. Blood Purif 32, 57-62.
123. Toledo J, Vanderstichele H, Figurski M, Aisen P, Petersen R, Weiner M, Jack C, Jagust W, Decarli C, Toga A, Toledo E, Xie S, Lee V, Trojanowski J, Shaw L (2011) Factors affecting Afj plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122, 401-413.
124. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simon-sick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB (2011) Association of plasma fj-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-266.